STOCK TITAN

Angiodynamics - ANGO STOCK NEWS

Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.

AngioDynamics Inc. (ANGO) develops minimally invasive medical devices for oncology, vascular, and surgical treatments. This page aggregates official news and press releases about product innovations, financial performance, and strategic initiatives.

Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study results, and market expansions. Content spans earnings announcements, technology partnerships, and FDA clearances relevant to interventional radiology and cancer treatment advancements.

All materials are sourced directly from the company and reputable financial publications. Bookmark this page for structured access to ANGO's evolving role in medical device innovation without promotional bias.

Rhea-AI Summary

AngioDynamics (NASDAQ: ANGO) announced its upcoming virtual Investor & Technology Day on July 13, from 9:30 to 11:30 a.m. ET. The event will feature presentations from the executive leadership team, discussing the company’s growth strategy, key technology platforms, and financial goals. Interested parties can register via the company’s website. A live webcast and archive of the presentation will also be available on the Investors section of the AngioDynamics website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
-
Rhea-AI Summary

AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q4 and fiscal year 2021 on July 13, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET for management to discuss these results. Investors can dial in using a specified number or access through a webcast on the company's website. Additionally, AngioDynamics will host a virtual Investor & Technology Day on the same day at 9:30 a.m. ET. Details and registration information will be provided on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
conferences earnings
-
Rhea-AI Summary

AngioDynamics, Inc. (NASDAQ: ANGO) announced that it received 510(k) clearance from the FDA for the AlphaVac Mechanical Thrombectomy System, designed for non-surgical removal of thrombi or emboli. The commercial release is anticipated in the second half of 2021. Additionally, the Company will report its fourth quarter and fiscal year 2021 financial results on July 13, 2021, with a conference call scheduled at 8:00 a.m. ET, followed by a virtual Investor and Technology Day at 9:30 a.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
none
Rhea-AI Summary

AngioDynamics, Inc. (NASDAQ: ANGO), a top provider of minimally invasive medical devices, announced Jim Clemmer, President and CEO, will present at the UBS Virtual Global Healthcare Conference on May 25, 2021, at 12:00 p.m. ET. The live webcast can be accessed through the company’s website and will be available for replay afterward.

The company specializes in devices for vascular access, peripheral vascular disease, and oncology, with a product range that includes ablation systems and drainage products. For further details, visit www.angiodynamics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
-
Rhea-AI Summary

AngioDynamics (NASDAQ: ANGO) announced the submission of a 510(k) application to the FDA for its AlphaVac System on April 9, 2021. This innovative thrombectomy device aims to treat undesirable intravascular materials in the venous system and peripheral vasculature. The AlphaVac System combines a mechanical aspiration handle with a self-expanding funnel tip, enhancing control and minimizing blood loss during procedures. The company anticipates the release of AlphaVac in the latter half of 2021, pending FDA clearance, as part of its strategy to expand its thrombus management portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
-
Rhea-AI Summary

AngioDynamics (NASDAQ:ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Needham Virtual Healthcare Conference on April 12, 2021, at 8:45 a.m. ET. Investors can access the live webcast through AngioDynamics’ website, where a replay will also be available post-event. The company specializes in products for vascular access, peripheral vascular disease, and oncology, including ablation systems and vascular access products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
Rhea-AI Summary

AngioDynamics (NASDAQ: ANGO) reported its third-quarter fiscal 2021 financial results, showing a 2% year-over-year revenue growth to $71.2 million, despite COVID-19 challenges. Vascular Interventions and Therapies sales increased by 8.8% to $33.3 million. However, Oncology sales dropped by 10.1% to $13.1 million. The company recorded a net loss of $3.5 million, improving from a $5.7 million loss last year. The gross margin declined to 54.1% due to Auryon start-up costs and COVID-related impacts. Adjusted guidance for FY2021 is now $285-$288 million in sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.87%
Tags
-
Rhea-AI Summary

AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will take part in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum. The event is scheduled for 10:00 a.m. ET on March 24, 2021. Investors can access a live webcast through the company’s website, with replay availability post-event. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, offering a range of leading products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences
-
Rhea-AI Summary

AngioDynamics, Inc. (NASDAQ: ANGO) announces participation in a virtual fireside chat at the 31st Annual Oppenheimer Healthcare Conference. Scheduled for March 16, 2021, at 9:20 a.m. ET, CEO Jim Clemmer and CFO Stephen Trowbridge will discuss company insights. A live webcast will be available through the Company’s website, with replay options post-event. AngioDynamics specializes in innovative, minimally invasive medical devices for vascular access, oncology, and peripheral vascular disease, focusing on diverse product lines that enhance patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
conferences
Rhea-AI Summary

AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 FY2021 on March 30, 2021, before the market opens. Management will host a conference call at 8:00 a.m. ET to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13717367. The call will also be available via webcast on the AngioDynamics website, with a replay accessible shortly after the call concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
conferences earnings
Angiodynamics

Nasdaq:ANGO

ANGO Rankings

ANGO Stock Data

386.58M
38.33M
5.62%
84.63%
4.24%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LATHAM